FDA, Migraine

The US Food and Drug Administration announced that it had approved Aimovig for the preventive treatment of a migraine in adults. This drug is the first of its kind and it is FDA approved preventive migraine treatment which works as a new class of drugs by blocking the activity of calcitonin gene-related peptide. Aimovig treatment is done only once in a month with the help of self-injection.

The present way to prevent a migraine is through the pills which are designed and developed for epilepsy. The other conditions which arise due to this type of treatment as many patients face serious side effects when they take this treatment as a result they abandon this treatment in a midway.

FDA, Migraine

Eric Bastings, who is the M.D. of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research said, “Aimovig provides patients with a novel option for reducing the number of days with a migraine. We need new treatments for this painful and often debilitating condition.”   The patients who suffer from this usually describe a migraine as headache pain and an intense pulsing or throbbing pain which is present in one area of the head. The symptoms of a migraine are nausea, vomiting, and sensitivity to light and sound.

The affected people who are about one-third can be predicted for the arising of a migraine. It can predict because when it happens the people suffer from temporary loss of vision, zig-zag lines or flashing of lights. The people who have got this usually suffer from attacks which can be caused due to many factors like stress, bright flashing light, hormonal changes and unbalanced diet.

A study which was carried on migraine by taking about 955 participants who all have the history of an episodic migraine and is compared to Aimovig to placebo. They are treated for six months and Aimovig-treated patients show that they suffer from one or two monthly migraines than placebo. The second study was done and in this 577 patients were taken with the same history. They are treated for three months, and Aimovig-treated patients show one average migraine per month than placebo. The third study included 667 patients and in this study, they are treated for three months and Aimovig patients show about 2 percent less monthly migraine.

The drug Aimovig is developed with a target of developing a substance which is called CGRP. It will cost around $6,900 per year without any insurance.

LEAVE A REPLY

Please enter your comment!
Please enter your name here